Treatment with tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) decreased PDCD4 expression, which was attributable to proteasomal degradation mediated by PI3K-Akt-mTOR-p70S6K and facilitated by MEK-ERK signaling pathway [16]. This evidence concerns the gene MAPK1 and neoplasm.